Publication: Angioedema Activity Score (AAS): A Valid and Reliable Tool to Use in Asian Patients
Issued Date
2019-01-01
Resource Type
ISSN
23146141
23146133
23146133
Other identifier(s)
2-s2.0-85075177191
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
BioMed Research International. Vol.2019, (2019)
Suggested Citation
Kanokvalai Kulthanan, Leena Chularojanamontri, Chuda Rujitharanawong, Puncharas Weerasubpong, Karsten Weller, Marcus Maurer Angioedema Activity Score (AAS): A Valid and Reliable Tool to Use in Asian Patients. BioMed Research International. Vol.2019, (2019). doi:10.1155/2019/9157895 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/50355
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Angioedema Activity Score (AAS): A Valid and Reliable Tool to Use in Asian Patients
Abstract
© 2019 Kanokvalai Kulthanan et al. The Angioedema Activity Score (AAS) is recommended by the EAACI/GA2LEN/EDF/WAO guidelines for urticaria as the standard measure for assessing disease activity in patients with recurrent angioedema (RAE). To date, it has been translated into 80 languages for use in 52 countries, but it has not been formally validated in Asian patient populations. As RAE may be different in Asian and non-Asian patients, it is important to validate and characterize the reliability of tools to assess RAE disease activity in Asian patients. This study proposed to demonstrate the validity and reliability of the AAS in Asian patients. Accordingly, this study aimed to generate and validate the Thai version of the AAS and to characterize its reliability in Asian patients, specifically in Thailand. A structured translation was conducted with approval from the original authors. The Patient Global Assessment of Disease Activity (PGA-DA) was used as an instrument to compare with the Thai version of the AAS. In total, 86 patients with RAE participated in the study. Seventy-six (88%) patients had RAE with chronic spontaneous urticaria. The Thai AAS was found to be a valid and reliable instrument, with high convergent and known-groups validities, excellent internal consistency, and good test-retest reliability. The validity and reliability of the AAS for assessing RAE disease activity in Asian patients have been demonstrated by our study, making it the first to do so. This will help promote the use of the AAS, in clinical trials and practice, in Asia. It will also facilitate the comparison of disease activity in patients with RAE inside and outside Asia in future studies. However, a limitation of this study was its small number of patients.